VISTA: An Emerging Immune Checkpoint With Clinical Relevance Across Diverse Malignancies Authors: Hiba Laraki, Ibtissam Rezouki, Khalil Choukri, Abdallah Badou Published: 2025 ABSTRACT Immune checkpoint inhibitors (ICIs) offer tremendous promise as therapeutic targets for a range of tumor types, and their development is advancing rapidly in cancer treatment. Nevertheless, the limited efficacy of anti-PD-1/PD-L1 immunotherapy in several cancers has driven researchers to explore other immune checkpoints as potential therapeutic targets. The inhibitory V-domain Ig suppressor of T-cell activation (VISTA) appears to be a captivating candidate. As a member of the B7 family, VISTA is expressed on hematopoietic cells and has the ability to significantly suppress T cell function and the anti-tumor immune response. In this review, our objective is to shed light on the multifaceted potential of VISTA as a therapeutic target. We will highlight the expressions and role of VISTA in various cancer types. Subsequently, we will go through distinct potential VISTA ligands, while underscoring the role of the pathway within the tumor microenvironments (TME). Finally, we will conclude with a comprehensive overview of the latest clinical trials, highlighting VISTA's emerging potential in cancer treatment. INTRODUCTION Cancer remains one of the leading causes of death worldwide, with an estimated 10 million deaths in 2020 (1). While conventional treatments such as surgery, radiotherapy, chemotherapy, and hormone therapy have improved patients’ outcomes, their associated toxicities and limited efficacy in certain malignancies have underscored the need for more targeted and effective strategies. In this context, cancer immunotherapy has emerged as a transformative approach aimed at harnessing the immune system to recognize and eliminate tumors cells. Immunotherapy encompasses various approaches, including vaccines, adoptive T cell transfer, cytokine therapy, and monoclonal Abs (2345). Among the key players in antitumor immunity, T cells are central to orchestrating adaptive immune responses. Several studies have highlighted their essential role in both tumor clearance and immune regulation in cancer and other immunopathologies (6). However, in the tumor microenvironment (TME), T cell activity is often suppressed by inhibitory receptors, commonly known as checkpoint inhibitors (7). The most extensively studied immune checkpoints belong to the B7 family, including the PD-1, PD-L1, and CTLA-4. Targeting these pathways with monoclonal Ab, such as ipilimumab and tremelimumab (anti-CTLA-4), pembrolizumab and nivolumab (anti-PD-1), and atezolizumab and avelumab (anti-PD-L1), has yielded significant clinical responses across various cancer types (8910111213). Despite these breakthroughs in immunotherapy, some patients either fail to respond or eventually develop resistance to immune checkpoint blockade. Recent investigations have aimed to elucidate the multifactorial mechanisms underlying this resistance, whether innate or acquired, which are frequently linked to disruptions in the cancer-immunity cycle, as described by Chen and Mellman (1415). Therapeutic failure may arise from insufficient generation of anti-tumor T cells due to low tumor immunogenicity or insufficient immune cell (IC) infiltration into the tumor parenchyma, or discontinuous effective anti-tumor immune response (1617). The response to PD-1 targeted-immunotherapy in advanced cancers such as non-small cell lung cancer (NSCLC), melanoma, and renal cell carcinoma was about 18%, 28%, and 27% respectively, with durable responses lasting over a year in many cases treated with nivolumab. However, the trial also highlighted that despite these response rates, the overall impact on long-term survival was limited, and a significant proportion of patients did not achieve durable benefit (18). Moreover, targeting CTLA-4 using ipilimumab has shown limited efficacy and often requires longer durations to achieve clinical benefit, allowing tumors to progress during the treatment window (19). Moreover, anti-CTLA-4 therapy can lead to severe side effects leading to induced autoimmunity (20). To prevent toxicity and thwart resistance, combination therapies targeting immune evasion mechanisms within the TME are being developed, including identification of new, more effective immune checkpoints with limited side effects (2122). Among these emerging targets, V-domain Ig suppressor of T-cell activation (VISTA), a member of the B7 family, has gained increasing attention for its role in maintaining immune tolerance and promoting immunosuppression in the TME. In this review, we will demonstrate that targeting VISTA across various cancer types holds significant therapeutic potential, especially when combined with PD-1/PD-L1 pathway blockade. VISTA: NOMINATION, STRUCTURE, EXPRESSION AND FUNCTION VISTA, also known as Vsir, homologous PD1, differentiation of ESC-1, platelet receptor Gi24 precursor, and C10orf53 (2324252627), is a member of the B7 family that shares homology with PD-1 (23), PD-L1, and PD-L2 (282930). VISTA, consisting of 311 amino acids (aa), comprises a 96 aa cytoplasmic tail, a 20 aa transmembrane domain, a 130 aa extracellular IgV domain, and a 32 aa signal peptide (31). Unlike other immune checkpoints, VISTA can function as either a receptor or a ligand (32), and is expressed on Ag-presenting cells (APCs), tumor cells (TCs), as well as T cells (TCD4+, TCD8+, and Treg) with strong expression on myeloid cells (2431). However, VISTA is not expressed in either B cells or NK cells (3133). In vitro studies have shown that the expression of VISTA or the VISTA-Ig fusion protein on APCs serves as a ligand, which inhibits the proliferation of TCD8+ and TCD4+ cells while reducing the production of pro-inflammatory cytokines (such as IL-2, TNF-α, and IFN-γ). These findings indicate that VISTA functions as a co-inhibitory ligand for T cells (24313334). BINDING PARTNERS OF VISTA Recent research has identified several molecules that bind to VISTA, either as receptors or ligands (Fig. 1). Published studies have focused on four specific molecules, V-set and Ig domain containing (VSIG) 3/Ig superfamily member (IgSF) 11, VSIG8, leucine-rich repeats and Ig-like domains 1 (LRIG1), and P-selectin glycoprotein ligand-1 (PSGL-1). VISTA interactions with various ligands in different pH environments. VISTA-IgSF11 As a receptor, VISTA binds to IgSF11, also known as brain- and testis-specific Ig superfamily. IgSF11 was identified as a member of the IgSF that mediates the homophilic adhesion through calcium-dependent interactions (35). Studies have shown that IgSF11 was detected in testis, ovary and brain, as well as in neurons and glial cells (35). Compared to its expression in normal tissues, IgSF11 was highly expressed in gastric, colorectal and hepatocellular tumors (3637). The suppression of IgSF11by small interfering RNA (siRNA) inhibited the progression of gastric tumors, suggesting that this molecule could be considered as a therapeutic target for gastric cancer (GC) (37). Recent studies have shown that IgSF11 binds specifically to VISTA without interacting with other known B7 family members. This binding mediates inhibition of T cell proliferation as well as cytokines and chemokines production including IFN-γ, IL-2, CCL5/Rantes, CCL3/MIP-1α, and CXCL11/I-TAC (36). The VISTA-IgSF11 pathway has been investigated across various autoimmune and inflammatory diseases, as well as cancers, to elucidate the mechanisms regulating the IC function, with a particular focus on T cell activity (343839). These reports suggest that the VISTA-IgSF11 pathway could be considered as a promising therapeutic target for these conditions in the future. VISTA-VSIG8 VSIG8, also known as C1orf204, is a 45 kDa type I transmembrane protein belonging to the IgSF (40). By inhibiting human T cell proliferation and cytokine production including IL-2, IFN-γ, IL-17, IL-6, and IL-19, VSIG8 plays a crucial negative regulatory role in T cell responses. Consequently, VSIG8 has emerged as a novel immune checkpoint that could potentially serve as a therapeutic target for cancer treatment (40). Recent research has elucidated the function of VSIG8 as a VISTA receptor. The interaction between these two molecules facilitates the suppression of T cell activity (4142). However, further investigations are required to gain a better understanding of the potential role of VISTA and VSIG8 interaction in cancer immunotherapy. VISTA-LRIG1 LRIG1 is a transmembrane protein that functions by interacting with receptor tyrosine kinases and Ig proteins, thereby preventing tumor growth and promoting normal cell division. Recent research has identified this molecule as one of the foremost candidates for the VISTA receptor (4344). In certain cases, anti-LRIG1 Abs disrupt the interaction between VISTA and LRIG1, thereby activating an immune response that can be leveraged to treat various types of cancers or immune disorders (WO2019165233, WO2021047104). Given the promising implication of the VISTA/LRIG1 pathway, it warrants further investigations and studies. VISTA-PSGL-1 When the pH of the environment is acidic, VISTA binds to its receptor PSGL-1, and acts as a ligand. This binding is facilitated by charged interactions between the sulfated tyrosine and protonated histidine residues (45). PSGL-1 is an adhesion molecule expressed by T cells and many other hematopoietic cells, which helps control the migration of naive, effector, and memory T cells. Studies have shown that deficiency of PSGL-1 leads to the proliferation of naive T cells, the production of anti-tumor cytokines by activated T cells, and downregulation of PD-1, thereby enhancing the antitumor immune responses (464748). Recent research suggests that PSGL-1 has the strongest transcriptional correlation with VISTA compared to other candidates, including VSIG3, LRIG1, and VSIG8. Moreover, spatial analyses suggest that the interaction interface and molecular proximity of VISTA/PSGL-1 may parallel that of PD-1/PD-L1 complexes (43), further highlighting the potential relevance of the VISTA-PSGL-1 axis in immune checkpoint blockade strategies. IMMUNOSUPPRESSIVE EFFECTS AND PROGNOSTIC VALUE OF VISTA IN DIFFERENT CANCERS VISTA has emerged as a promising therapeutic avenue for various types of cancer, such as GC, oral squamous cell carcinoma (OSCC), prostate cancer, melanoma, acute myeloid leukemia (AML), hepatocellular carcinoma (HCC), colorectal cancer (CRC), ovarian cancer, lung cancer, pancreatic cancer, renal cell carcinoma, brain cancer, and breast cancer (Table 1). Table 1Prognostic significance of VISTA across various malignanciesCancer typeVISTA effectClinical/functional effectKey referencesGCInhibitory■ VISTA modulates TAMs and CD8+ T cells, enabling immune evasion.(5051)■ Expression linked with tumor progression and PD-L1.■ Reduced expression in GC cell lines.■ Combined PD-1/PD-L1/VISTA blockade proposed as therapy.OSCCInhibitory■ Elevated VISTA expression; correlated with CD11, CD33, PD-L1, CTLA-4, PIK3, pSTAT3.(245253)■ Dual PD-L1/VISTA blockade enhances anti-tumor immunity. VISTA & CD8 potential survival predictors.MelanomaInhibitory■ VISTA correlates with inflammatory cells and PD-1.(565759)■ High VISTA linked to poor survival.■ Dual blockade (VISTA + PD-1) improves tumor control.CRCInhibitory/stimulatory■ VISTA high on TILs, correlated with immune-regulatory factors.(6062)■ Linked to immune escape but also prolonged survival (early stage, MMR deficiency, high lymphocyte infiltration).Ovarian & endometrial cancerInhibitory/stimulatory■ VISTA expressed in immune, tumor, endothelial cells.(64)■ Enriched in PD-L1-negative ovarian cancers.■ Correlated with PFS, OS in HGSOC; favorable prognostic indicator.Pancreatic cancerInhibitory■ Highly expressed in tumors with cytolytic activity.(666768)■ VISTA+ macrophages reduce CD8+ T cell cytokine production.■ Anti-VISTA Abs suppress liver metastasis.NSCLCImmunomodulatory■ High VISTA on TCs.(69707172)■ Associated with TILs, PD-1/PD-L1, and survival.■ High VISTA+ Th1 infiltration linked to poor prognosis.Renal cell carcinomaInhibitory■ VISTA upregulated in macrophages in metastatic tumors.(7374)■ negatively correlated with CD8+ infiltration.■ Blockade reduces tumor growth.Prostate cancerInhibitory■ VISTA expressed on CD4, CD8 T cells & CD68+ macrophages.(75)■ Reduces IFN-γ and TNF-α. Potential compensatory mechanism post-ipilimumab.HCCInhibitory/stimulatory■ Correlated with CD8+ TIL density, pathological grade, and cirrhosis.(76)■ VISTA+ tumors linked to prolonged OS. Dual CD8 + VISTA expression associated with better prognosis.AMLInhibitory■ High VISTA on blasts & MDSCs, suppressing CD8+ T cells.(77787980)■ Combination PD-1 + VISTA blockade prevents relapse and resistance in models.GliomaInhibitory■ Overexpressed in high-grade gliomas.(2881)■ Correlated with poor OS and IDH-wild type tumors.■ VISTA KO mice resist tumor induction.Breast cancerInhibitory/stimulatory■ VISTA upregulated in tumors vs normal tissue.(82838485)■ Associated with HER2+ and basal subtypes.■ Correlated with CD4+, CD8+, CD68+ TILs.■ Favorable survival in ER−, PR−, basal type BC.■ Linked to EMT.TDM, tumor-derived macrophages; PFS, progression-free survival; KO, knockout; IDH, isocitrate dehydrogenase; HER2, human epidermal growth factor receptor 2. Prognostic significance of VISTA across various malignancies TDM, tumor-derived macrophages; PFS, progression-free survival; KO, knockout; IDH, isocitrate dehydrogenase; HER2, human epidermal growth factor receptor 2. In GC GC is the fifth most common cancer globally and the third leading cause of cancer-related mortality. Despite a reduction in the mortality rate in recent years, GC is still considered a life-threatening disease (49). The study by Cao et al. (50) revealed that VISTA was mainly expressed on tumor-associated macrophages (TAMs) in GC. The co-culture of this population with VISTA decreased the function of TCD8+ cytotoxic cells, and thus its blockage reprogrammed the TAM population and reactivated TCD8+, thus promoting TC apoptosis, indicating the potential involvement of VISTA in the development of GC (50). Moreover, Böger et al. (51) demonstrated, through an immunohistochemical study, that VISTA expression was observed in 8.8% of TCs and 83.6% of tumors infiltrating ICs of patients with GC, and also found that VISTA was significantly associated with the expression of PD-L1. This association could be used in immune escape mechanisms linked to VISTA/PD-L1/PD-1. The co-expression of VISTA/PD-L1 highlights the potential of combined blockade as a potential GC treatment option (51). Overall, these findings suggest the significance of VISTA in GC development and progression, indicating the potential use of VISTA/PD-L1/PD-1 blockade as a novel treatment strategy. In human OSCC OSCC, also known as epidermoid oral carcinoma, is a prevalent malignant tumor characterized by abnormal lesions or malignant hyperplasia of the soft and hard tissues of the oral cavity (1). Recent studies by Wu et al. (52) have demonstrated that VISTA expression is significantly higher in human OSCC samples compared to normal oral mucosa. Moreover, VISTA expression was found to be positively correlated with CD11 and CD33, as well as PD-L1 and CTLA-4, and with immune-related pathways such as PI3K and p-STAT3 (52). Building upon these findings, Liu et al. (53) showed that dual PD-L1 and VISTA blockade can generate antitumor immunity in OSCC. Notably, Wang et al. (24) confirmed that VISTA blockade can effectively mitigate tumor growth, particularly when combined with an anticancer vaccine. Thus, as an immune checkpoint, VISTA has been shown to correlate with PD-L1, CTLA-4, PI3K, and p-STAT3 in OSCC, suggesting a significant regulatory role in antitumor immunity. Additionally, the combined assessment of VISTA and CD8+ T-cell infiltration may have prognostic value for OSCC patients and highlights their potential as targets for immunotherapy. In melanoma cancer Melanoma is an aberrant proliferation of malignant melanocytic cells, exhibiting a high metastatic potential compared to other skin cancers. Patients diagnosed with metastatic melanoma have a poor prognosis with a median survival of merely 8 months (54). Despite the awareness of risk factors, the incidence of melanoma is rising in all age groups, with increasing mortality rates among the elderly, particularly those with a lean physique (55). A recent study revealed a positive correlation between VISTA expression, neutrophil infiltrate, and PD-1 density on tumor infiltrating inflammatory cells. Moreover, low survival rates were observed in these cases, providing strong support for VISTA as a promising immunotherapeutic target for the disease in its early stages (56). Although PD-1 inhibitors appear to improve response and survival in the treatment of metastatic melanoma, some patients develop resistance. In the study by Kakavand et al. (57), the authors reported increased VISTA expression on tumor-infiltrating lymphocytes (TILs), similar to PD-L1, which may promote immune escape, along with a significant increase in FoxP3+ regulatory T cells that exert an immunosuppressive role in TME. In addition, a combined block of VISTA and PD-1 could represent a new therapeutic target, which might lead to improved response in these patients (58). In similar research, on mice transplanted with melanoma. Results showed that VISTA blockade resulted in increased tumor-specific CD4+ and CD8+ T cells, decreased regulatory T cells (FoxP3+), and delayed tumor progression in genetically predisposed mice (33). Combined anti-VISTA and anti-PD-1 therapy in murine models of melanoma was proven to be more effective than monotherapy using anti-VISTA alone (59). In CRC The expression and role of VISTA in CRC has been the subject of numerous investigations. Xie et al. (60) demonstrated that CRC shows higher VISTA expression compared to PD-L1. In addition. VISTA showed higher level in tumor tissues of patients with CRC compared to normal tissues. In contrast to PD-L1, frequently expressed by TCs (CD456), VISTA is mainly expressed by lymphocytes infiltrating tumor (CD45+). Additionally, a strong positive correlation was detected between VISTA and other inhibitory molecules, such as T cell immunoreceptor with Ig and ITIM domains, hepatitis A virus cellular receptor 2, B and T lymphocyte attenuator, PD-L1, and PD-1. Moreover, VISTA expression was found to be positively associated with TGF beta 1, FOXP3, and even M2 macrophage signature genes, such as CD14, CD68, and CD163 (60). These findings suggest that VISTA may play a role in immune escape in CRC. A recent study published by Zong et al. (61) analyzed the expression of VISTA in tissue microarrays on a large cohort of patients with stage I–III CRC. They revealed that the significant presence of VISTA in tumor-infiltrating ICs was linked to the advanced stages of tumor N0, T1-2, has a low tumor grade, with poor repair state (mismatch repair) and prolonged survival in patients with CRC (61). The study by Wu et al. (62) showed that VISTA was associated with stromal differentiation, early tumor stage, elevated TILs, BRAF mutation and longer survival. In the same research, the authors conclude that VISTA could be a clinically relevant biomarker for the treatment of CRC. These results suggest that inhibition of VISTA in combination with other immunotherapies may be beneficial, also pointing out that it is linked to a better prognosis (62). Studies by Lines et al. (31), and Correale et al. (63), have shown that negative regulation by VISTA or Treg FoxP3 could modulate the MET and improve survival in patients with CRC. Taken together, these results elucidate the potential promising role of VISTA as a therapeutic target in CRC. In human ovarian and endometrial cancer Ovarian cancer is a particularly aggressive form of gynecological cancer with the highest incidence rate globally. More than 75% of patients are diagnosed at an advanced stage (III/IV), which significantly impacts treatment outcomes. In fact, the overall 5-year survival rate is less than 30% (64). Zong et al. (64) have recently shown that VISTA is highly expressed in patients with high-grade ovarian cancer, and the latter has gained much attention as a potential new target for cancer immunotherapy. In this study, the authors have evaluated the expression of VISTA and PD-L1 in ovarian epithelial cancer and found that the VISTA protein was not only expressed in tumor infiltrating ICs, but also in the TCs themselves and in the endothelial cells. As a result, VISTA expression in PD-L1 negative ovarian cancer is associated with improved survival, especially in patients whit high-grade serous ovarian carcinoma (HGSOC) (65). In line with the results of Li et al. (38), the study also showed that PD-L1 expression was not associated with survival in patients with ovarian cancer. Thus, VISTA appears to be a favorable prognostic indicator in patients with HGSOC (64). The VISTA protein is often expressed in TCs, but not in ICs with negative PD-L1. This expression has been linked to the activation of certain genes involved in the regulation of the immune escape process. Moreover, its expression in TCs was associated with a prolonged survival of the patients. These observations revealed that the existence of VISTA in cancer cells was correlated to a favorable prognosis for patients with HGSOC. This suggests that VISTA could be a promising therapeutic target especially for PD-L1 negative tumors (64). In pancreatic cancer VISTA is among the immune checkpoint genes that exhibit high expression in pancreatic cancers (66). In order to elucidate the immune context of pancreatic cancers, Blando et al. (67) conducted a comparison of immune infiltration in pancreatic cancer with that in melanoma. The authors demonstrated that pancreatic tumors exhibit higher VISTA expression compared to melanoma. Additionally, the study identified VISTA+ macrophages as one of the potentially inhibitory cell types that can significantly alter clinical outcomes in these patients. Furthermore, engagement of VISTA resulted in reduced cytokine production by LTCD8 within metastatic pancreatic cancers (67). However, the administration of anti-VISTA Abs in mouse models of pancreatic ductal adenocarcinoma significantly reduced the frequency of liver metastasis (68). Taken together, these findings suggest that VISTA blockade may be a promising therapeutic strategy for patients with pancreatic cancer. In lung cancer The impact of VISTA has been described in various studies on NSCLC. Villarroel-Espindola et al. (69) demonstrated high expression of VISTA in human NSCLC, as well as a significant positive association with TILs, PD-1, and its ligand, PD-L1. Hence, an increase in VISTA expression was correlated with a low mutational load and also with the absence of epidermal growth factor receptor mutations. However, various research on NSCLC has shown that VISTA expression on TCs promotes a TME characterized by the presence of cytotoxic TCD8+ lymphocytes. This expression is linked to a better antitumor response and predicts an extended overall survival (OS) of 5 years (6970). In contrast, two recent studies investigated the clinical prognosis of VISTA expression in NSCLC patients. The authors revealed a high infiltration of VISTA+ Th1 cells in tumor tissues, which were positively correlated with poor patient survival, high mortality, and lymph node metastasis (7172). Furthermore, Ma et al. (71) studied the levels of Th1, Th2, Tregs, and Th17 cytokine secretion and macrophages in NSCLC patients with VISTA expression on CD4+ T cells, and they showed that the level of cytokines (IFN-γ, IL-2, IL-4, IL-10, IL-17, and IL-12p70) in VISTA+ TME CD4+ T cells was low compared with that in adjacent peritumoral tissues. All these results indicate the immunomodulatory role of VISTA and suggest that it could be used as a potential therapeutic target in human NSCLC. In renal cell carcinoma At the transcriptome and protein levels, researchers have explored the expression of VISTA and its impact on tumor immunity in clear cell renal cell carcinoma (ccRCC). Tronik-Le Roux et al. (73) observed an upregulation of VISTA on macrophages surrounding cancer cells within the metastatic environment of ccRCC. Similarly, Hong et al. (74) reported that ccRCC tumors exhibit elevated levels of VISTA expression in intratumoral myeloid cells compared to non-tumor tissues. The high expression of VISTA negatively correlates with the infiltration of TCD8+ lymphocytes, as well as the expression of granzyme B, perforin, and TNF-α (74). Additionally, the effect of VISTA blockade was studied using the RENCA RCC mouse model, where the authors noted a reduction in renal tumor growth with the use of anti-VISTA Abs compared to the control group, as well as treatment with anti PD-L1 (74). Taken together, these findings support the notion that VISTA plays a significant role in suppressing cancer immunity in ccRCC and highlights its potential as a target for immunotherapy in this type of cancers. In prostate cancer In order to gain a deeper understanding of the immune profile of prostate cancer, and to identify potential compensatory immune inhibitory pathways that may arise with immune checkpoint monotherapy, Gao et al. (75) conducted a clinical trial. This clinical trial involves ipilimumab plus androgen deprivation therapy administered prior to surgery in patients with localized and metastatic prostate cancers. The results of the study indicate a significant increase in VISTA expression in CD4 T cells, CD8 T cells, and particularly CD68+ macrophages. In addition, in vitro tests utilizing PD-L1 or VISTA protein revealed that T cells produced significantly less IFN-γ and TNF-α from prostate cancer patients. These findings strongly suggest that VISTA may act as an additional compensatory inhibitory mechanism in prostate cancers following ipilimumab therapy and could be used as a suitable target along with PD-1/PD-L1 pathway in combined immunotherapies. In HCC Zhang et al. (76) conducted a study to evaluate the expression and prognostic value of VISTA in HCC using two different cohorts. The authors also identified TMEs based on VISTA and tumor-infiltrating CD8+ lymphocytes (TILs). The study included 183 HCC cases, out of which 29.5% (54/183) of the HCC tissues expressed VISTA, with 16.4% (30/183) of tissues showing VISTA expression in TCs, 16.9% (31/183) of tissues showing VISTA expression in ICs, and 3.8% (7/183) of tissues showing VISTA expression in both TCs and ICs. VISTA expression was significantly associated with tissues showing high pathological grades (p=0.038), absence of liver cirrhosis (p=0.011), and high CD8+ TIL density (p<0.001), which represented 33.3% (61/183) of HCC tissues. Patients with VISTA-positive staining in TCs (p=0.037), but not in ICs (p=0.779), showed significantly prolonged OS compared to those with VISTA-negative expression, according to Kaplan-Meier curves. The authors also performed both univariate and multivariate analysis of OS in HCC patients and found significant correlations between OS and TNM stage (p<0.001), tumor size (p=0.002), VISTA expression in TCs (p=0.038), and CD8+ TILs (p=0.008). The authors further examined the correlation between the prognosis of HCC patients and the four immune subtypes based on VISTA and CD8+ TIL classification (VISTA+/CD8+ [16.9%, 31/183], VISTA+/CD8− [12.6%, 23/183], VISTA−/CD8+ [16.4%, 30/183], and VISTA−/CD8− [54.1%, 99/183]) using Kaplan-Meier curve analysis. They revealed that the VISTA+/CD8+ double-positive subtype had significantly prolonged OS than the other subtypes (p=0.023). In HCC, the combination of VISTA expression and TCD8+ cells appears to confer a favorable immune microenvironment and improved OS (76). This suggests that VISTA may be a potential target for immunotherapy of CHC. In AML The expression of VISTA in AML has been the focus of extensive research. According to Lamble et al. (77), AML patients exhibit a high proportion of blasts with elevated VISTA expression. Wang et al. (78) also found that patients newly diagnosed with AML had increased levels of VISTA expression on myeloid-derived suppressor cells (MDSCs) compared to healthy controls. Furthermore, a reduction in the inhibition of T CD8 cell activity by MDSC was observed in AML upon specific siRNA-mediated VISTA elimination, indicating that VISTA exerts a suppressive effect on T cell anti-leukemic response (78). In another study, utilizing a mouse model of AML, Kim et al. (79) demonstrated that the VISTA protein is highly expressed in the bone marrow of human AML donors. They also observed that PD-1H knockout (KO) mice had improved survival compared to their WT counterparts and that the growth of AML murine cells in vivo was attenuated in PD-1H KO mice. These findings indicate that VISTA can lead to immune evasion in AML murine models (79). Furthermore, it has been proposed that the combination of VISTA and PD-1 blockade may be a useful strategy for preventing AML recurrence and overcoming treatment resistance (7880). Overall, the studies discussed here highlight the importance of VISTA in AML and its potential as therapeutic target. Further research is needed to fully elucidate the role of VISTA in AML and to evaluate its clinical significance. In brain cancer In a study conducted by Flies et al. (28), it was observed that VISTA-deficient animals exhibited marked resistance to tumor induction and CD4+ T cell depletion in a murine brain glioma. Another investigation by Ghouzlani et al. (81) revealed that glioma tissues had significantly higher levels of VISTA compared to healthy donor PBMCs. Additionally, patients with high-grade gliomas (grade III/IV) displayed overexpression of VISTA in comparison to those with low-grade gliomas (grade I/II), both at the mRNA and protein levels. The expression of VISTA mRNA showed favorable associations with other essential immune checkpoint regulators. Furthermore, the isocitrate dehydrogenase mutation exhibited a negative correlation with high VISTA transcript levels, which were also linked to poor OS in glioma patients (81). These findings collectively demonstrate a correlation between high levels of VISTA expression and poor prognosis in glioma patients, indicating that VISTA may play a crucial role in glioma progression and could represent a promising new therapeutic target. In breast cancer Several researchers have investigated the predictive impact of VISTA in breast cancer, with contradictory findings. VISTA expression was observed in both immune and TCs of breast cancer patients. Furthermore, compared to adjacent tissue, tumor tissue demonstrated an upregulation of this immune checkpoint in the Mammary TME (82838485). Moreover, VISTA was positively associated with grade, estrogen receptor-negative (ER−), progesterone receptor-negative (PR−), human epidermal growth factor receptor 2-positive, lymph node status, and human epidermal growth factor receptor 2-enriched and basal-like subtypes (828384). In contrast, Cao et al. (85) found that VISTA expression on ICs was positively associated with the absence of lymph node metastasis, American Joint Committee on Cancer stages I and II, and basal-like subtype. Furthermore, VISTA expression was favorably correlated with PD-1, PD-L1, specific CD4+ and CD8+ TILs, as well as CD68+ TAMs in breast cancer (82838485). Moreover, our research demonstrated for the first time that VISTA overexpression in breast cancer cells could be associated with the EMT process (84). On the other hand, it has been reported that patients with high VISTA expression had improved relapse-free and OS in breast cancer patients with stage T1-2N0, ER−, PR−, and basal type (85). These findings support VISTA's regulatory function in antitumor immunity and suggest that VISTA could be targeted therapeutically for breast cancer. In conclusion, the expression of VISTA plays an important role in breast cancer progression and prognosis. Further studies are needed to clarify the contradictory findings and to explore the potential use of VISTA as a therapeutic target for breast cancer. VISTA’s function varies depending not only on cancer types, as shown in Table 1, but also on multiple biological and therapeutic factors. Those determinants include the cellular expression and localization, the nature of its ligand interactions, the molecule used to target VISTA, and the tumor immune microenvironment. Within the TME, VISTA expression on different immune subsets shapes their behavior: on naïve CD4+ T cells, it maintains quiescence and enforces tolerance, while on MDSCs and macrophages, it suppresses both innate and adaptive immunity, thereby dampening antitumor responses (2486). The localization of VISTA further influences outcomes: high expression on MDSCs, Tregs, and macrophages strongly promotes immunosuppression, whereas expression on TCs or stromal compartments can yield more context-dependent effects, sometimes correlating with favorable prognosis (169). Ligand interactions also determine its activity; under acidic conditions typical of the TME, VISTA binds PSGL-1 to inhibit T cell responses, and blockade of this interaction restores effector T cell activity (3645). Finally, therapeutic modulation is another variable, where antagonistic anti-VISTA Abs enhance CD4+ and CD8+ T cell activation and IFN-γ production, improving tumor control, while agonistic Abs can stabilize Tregs and promote immune tolerance (3386). These variables shape whether VISTA acts predominantly as an immune inhibitor or, in select contexts, as a regulator of tolerance, Whereas the therapeutic factor seems to be crucial in finding the right VISTA-targeting molecule. CLINICAL TRAILS Several clinical trials are currently underway to assess the effectiveness of anti-VISTA therapy (Table 2). Table 2Summary of clinical trials investigating anti-VISTA therapeutics in cancerMoleculeManufacturerPhase/trial IDPrimary endpointsSecondary endpointsReported clinical outcomesCA-170Curis/AurigenePhase 1 (NCT02812875) (87)Safety, tolerability, PKPD biomarkers, preliminary efficacyEvidence of T-cell activation ex vivo; some SD in solid tumors/lymphomas; no clear objective responses; mechanism revised likely VISTA-driven, not PD-L1.CI-8993ImmuNext/CurisPhase 1 (NCT04475523; restarted 2020) (91)Safety, MTD, PK/PDImmunomodulation (MDSCs, DCs, T cells), preliminary efficacyEarly Janssen trial stopped due to CRS.Curis re-launched with step-dosing; updated 2023 data showed manageable safety, some immune activation; no confirmed responses.HMBD-002HummingbirdPhase 1/2 (NCT05082610) (97)Safety, tolerability, PK/PDCytokine induction, T-cell activity, preliminary anti-tumor efficacyPreclinical: elevated IFN-γ and TNF-α, decreased CD14+ monocytes, tumor inhibition.Human trial ongoing; no published ORR yet. Early reports: favorable tolerability.KVA12123KinetaPhase 1/2 (NCT05708950) (101102)Safety, DLTs, RP2D, PK/PDImmune activation, tumor response (per RECIST)SITC 2023: No dose-limiting toxicities; signs of immune activation; early signals of anti-tumor activity in combination with pembrolizumab; efficacy outcomes pending.PK, pharmacokinetics; PD, pharmacodynamics; SD, stable disease; MTD, maximum tolerated dose; ORR, objective response rate; DLT, dose-limiting toxicity; RECIST, Response Evaluation Criteria in Solid Tumors; SITC, Society for Immunotherapy of Cancer. Summary of clinical trials investigating anti-VISTA therapeutics in cancer PK, pharmacokinetics; PD, pharmacodynamics; SD, stable disease; MTD, maximum tolerated dose; ORR, objective response rate; DLT, dose-limiting toxicity; RECIST, Response Evaluation Criteria in Solid Tumors; SITC, Society for Immunotherapy of Cancer. CA-170 A multicenter phase 1 trial (NCT02812875) was developed to investigate CA-170 as a dual inhibitor of the PD L1, PD-L2, and VISTA checkpoints. CA-170 was administered orally to adult patients with solid tumors and advanced lymphomas, with the aim of evaluating its safety, pharmacokinetics, pharmacodynamics, and clinical effects (87). The ex vivo preclinical data demonstrated that CA-170 induced T-cell proliferation and activation within the TME, with concomitant cytokine production (IFN-γ). It showed significant anti-tumor efficacy in several immunocompetent murine tumor models, both as monotherapy and in combination with approved therapeutic agents (87). Importantly, CA-170 is notable for being the only small-molecule antagonist targeting immune checkpoints that has progressed through multiple clinical trials, including phase 1 and phase 2 studies. However, recent structural and biophysical studies, including those by Musielak et al. (88), have questioned the initially proposed dual activity of CA-170. Using techniques like surface plasmon resonance and nuclear magnetic resonance, these studies failed to demonstrate direct binding of CA-170 to PD-L1, suggesting that its immunomodulatory effects may be primarily mediated via VISTA inhibition rather than PD-L1 blockade. Consequently, although CA-170 represents a promising therapeutic candidate, further mechanistic studies are needed to fully characterize its molecular targets and clarify its clinical potential. CI-8993 CI-8993 is a human IgG1 kappa monoclonal Ab designed to antagonize the VISTA signaling pathway. Preclinical data demonstrated that CI-8993 binds to VISTA on monocytes and T cells, thereby reducing the frequency of monocytic MDSCs and increasing the activation of dendritic cells. This reversal of VISTA-induced suppression enhances T cell immune responses in the TME by increasing T lymphocyte mediated cytokine production and inhibiting tumor growth. As a results, CI-8993 enhances the infiltration, proliferation, and activation of CTLs within the TME (89). In 2016, a phase 1 clinical trial was launched to investigate the safety, pharmacokinetics, and pharmacodynamics of CI-8993 in patients with advanced solid tumors; however, a transient cytokine release syndrome (CRS), a known immune-related adverse effect, was noticed during the trial in one of the participant (909192), in which the trial was closed. Later in January 2020, a phase 1 NCT04475523 trial was relaunched to evaluate many anti-VISTA Abs, including CI-8993 (91), the dose-escalation study progressed until its completion in May 2023, enrolling 26 patients. Despite promising immunomodulatory effects (93). No approvals have been recorded from Food and Drug Administration, the European Medicines Agency or other regulatory agencies to date (94), probably because of CRS as a treatment-related adverse event. Even if CRS was controlled in NCT04475523 trial. CI-8993 remains an investigational agent that requires proof of safety, and manageable side effect profile before any potential authorization. HMBD-002-V4C26 (HMBD-002) HMBD-002 is a novel IgG4 monoclonal Ab that selectively binds to the C–C’ loop of VISTA, blocking its interaction with ligands such as VSIG3 and thereby disrupting VISTA-mediated immunosuppression (95). Elevated VISTA expression in triple-negative breast cancer (TNBC) and NSCLC highlights these malignancies as promising targets for HMBD-002 therapy (96). In preclinical studies, HMBD-002 treatment significantly reduced tumor growth and improved survival in colorectal, breast, and lung cancer xenograft models. Mechanistically, its administration induced a dose-dependent increase in pro-inflammatory cytokines (IFN-γ, TNF-α) while limiting the expansion of CD14+ monocytes (96). Building on these findings, A phase 1/2, open-label, multi-center trial (NCT05082610) is currently evaluating HMBD-002 as monotherapy and in combination with pembrolizumab to assess safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy in patients with advanced solid tumors, including TNBC (9798). KVA12123 KVA12123 is a fully human IgG1 monoclonal Ab that targets VISTA and is engineered to bind at both physiological and acidic pH (99). Preclinical studies demonstrated potent antitumor activity (including CT26 and other xenograft models), with treatment inducing dose-dependent increases in IFN-γ and TNF-α and reducing CD14+ monocyte expansion—consistent with reversal of a suppressive TME (99). Toxicology and tolerability studies in rodents and cynomolgus monkeys showed acceptable tolerability and serum exposure, and ex vivo human PBMC/whole-blood assays did not evidence cytokine release (99). Based on these data and the observation of elevated VISTA expression across several tumor types, KVA12123 is being evaluated in phase 1/2 VISTA-101 study (NCT05708950). Early clinical updates report that multiple monotherapy dose levels have been cleared with no dose-limiting toxicities, combination cohorts with pembrolizumab are tolerable, KVA12123 effectively binds and blocks nearly all available VISTA receptors in patients, without safety concerns, which validates using that dose in further clinical trials targeting tumors that highly express VISTA (100). CONCLUSION VISTA has emerged as a critical immune checkpoint with unique structural and functional characteristics distinguishing it from other members of the B7 family. Its broad expression on various ICs, particularly myeloid and T cells, positions it as a central regulatory of immune tolerance within the TME. Unlike other checkpoints, VISTA functions both as a ligand and a receptor, contributing to its complex regulatory capabilities. Recent studies have identified binding partners for VISTA, such as PSGL-1 and VSIG3. These interactions are particularly relevant under acidic conditions commonly found in the TME, where they facilitate VISTA mediated immunosuppression. Preclinical and clinical studies have consistently demonstrated the immunosuppressive role of VISTA across multiple tumor types, where its high expression often correlates with poor prognosis and resistance to existing immunotherapies. These findings highlight its prognostic value and justify ongoing efforts to target VISTA as a therapeutic strategy. Current clinical trials evaluating VISTA inhibitors both as monotherapy and in combination with PD-1/PD-L1 blockade reflect growing interest in overcoming immune escape mechanisms in refractory cancers. Although several challenges remain, including the full elucidation of VISTA’s ligands and signaling pathways, early clinical outcomes are promising. In summary, VISTA represents as next-generation immune checkpoint target with the potential to enhance cancer immunotherapy. Continued investigation into its biology and therapeutic modulation may significantly expand treatment options and improve outcomes for patients with various malignancies.